Pharmaceutical doses that worked before now overshoot. Alcohol stops being enjoyable. Foods that were fine for thirty years suddenly trigger reactions. The body reset to a different baseline, and the new baseline is more reactive across nearly every chemical class.
Survivors describe needing one quarter to one half of the previously normal dose of most prescription medications to get the intended effect. Sedatives knock them out for a full day instead of a night. SSRIs trigger side effects at starting doses. Anesthesia for routine procedures becomes a problem the anesthesiologist has to manage carefully, because the survivor goes under fast and stays under longer than the protocol predicts. Many long-term experiencers carry a written note for their dental work and emergency room visits.
The pattern is described in print by Atwater, who documented it across her interview database, and is referenced clinically by Greyson, who notes that NDE survivors require lower analgesic doses for post-surgical pain than matched controls. The mechanism is not understood. It is consistent enough that some anesthesiologists who have worked with NDE survivor populations adjust their starting doses by reflex.
"My dentist learned the hard way. He gave me the standard dose of lidocaine for a filling, and my whole face went numb for nine hours. I lost the ability to talk for the afternoon. He cut it in half the next time, and that was still too much. We are now at a quarter of his normal dose for a man my size, and that is what works." — experiencer interview, Journal of Near-Death Studies, 2011
Almost universally, long-term experiencers stop drinking, or cut back dramatically. The standard report is not that they decided alcohol was bad, it is that it stopped being pleasurable. One glass produces the wrong effect: a heavy, dissociated, foggy feeling rather than the relaxation they remembered. Many survivors quit social drinking inside a year. The same pattern shows up for caffeine in a subset of survivors, and for cannabis in a much larger subset, where what was an enjoyable mild intoxication becomes uncomfortable or frankly unpleasant.
New allergies appear. Foods that were eaten weekly for decades start producing digestive symptoms, skin reactions, or fatigue. Environmental sensitivities increase: perfumes, cleaning products, synthetic fabrics, off-gassing from new furniture. Some survivors develop multiple chemical sensitivity profiles that look clinically similar to what is documented in chronic-fatigue and Lyme-disease populations, despite not having those etiologies.
Liver and detoxification changes. One hypothesis, supported by some functional medicine practitioners but not by mainstream pharmacology, is that the metabolic stress of the near-death event produces lasting changes in hepatic cytochrome P450 activity. This would explain the lower effective doses of most pharmaceuticals. The mainstream objection is that the studies have not been done, and the body of clinical pharmacology does not support a stable shift of this magnitude from an acute stress event.
Autonomic dysregulation. Same family of explanations as the sensory-sensitivity cluster on (see Light and Sound Sensitivity). The sympathetic and parasympathetic nervous systems were pushed past their normal operating range during the crisis, and they did not fully recover. Heart-rate variability changes, blood pressure changes, and gastrointestinal reactivity changes are documented in the long-term follow-up data. New food sensitivities are consistent with this picture.
The "thin body" hypothesis. Survivors' own framing. The experience changed the relationship between consciousness and the body, and the body now responds to inputs that it ignored before. This is descriptive rather than mechanistic. It is the framing most experiencers use, because it matches what it feels like from the inside.
Selection and reporting bias. The skeptical position. Survivors are paying attention to their bodies after the event in ways they were not before. Sensitivities they had all along now register. The rejoinder is that the dose-response data on anesthesia is observable from the clinician's side, not the patient's, and the clinician-reported version of the same pattern is in the literature.
Most long-term experiencers learn the new baseline within a few years and live within it. They tell their doctors to start at low doses and titrate up. They keep clean diets. They quit alcohol or hold it to a few drinks a year. They watch the new perfume their spouse buys. The accommodation is permanent. The body's old chemical tolerances did not return at five-year follow-up in any of the major studies.